PPLPHARMA vs MOLBIO: Stock Comparison
Head-to-head financial and trading comparison between Piramal Pharma Limited (PPLPHARMA) and Molbio Diagnostics Limited (MOLBIO) in the Cross-Sector Peers sector.
PPLPHARMA
NSE: PPLPHARMAMOLBIO
NSE: MOLBIOKey Metrics Comparison Table
| Metric | PPLPHARMA | MOLBIO | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹196.88 | ₹1,438.60 | — |
| 1-Year Price Return | +32.32% | +38.1% | MOLBIO (5.78% higher) |
| 52-Week High | ₹226.62 | ₹1,544.70 | — |
| 52-Week Low | ₹148.79 | ₹1,036.65 | — |
| 30-Day Annualized Volatility | 32.84% | 95.93% | PPLPHARMA (Steadier) |
| 30-Day Average Daily Volume | 3,775,308 | 3,210,458 | PPLPHARMA (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between PPLPHARMA and MOLBIO, which stock gave better returns over the last year?
MOLBIO has outperformed PPLPHARMA over the past 12 months with a gain of 38.1% compared to 32.32%.
Which stock is less volatile: PPLPHARMA or MOLBIO?
PPLPHARMA demonstrated lower price volatility (32.84% annualized) compared to MOLBIO (95.93%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of PPLPHARMA vs MOLBIO?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are PPLPHARMA and MOLBIO direct sector competitors?
Yes, both companies operate within the Cross-Sector Peers sector in India and are actively tracked as sector peers by institutional and retail market participants.